Clarivate: The Data Intelligence Company Flying Under the Radar

"Clarivate owns some of the most defensible data assets in the world. Web of Science. Derwent. Cortellis. These aren't household names, but inside a university library, a patent law firm, or a biopharma R&D team, they're the only gas station for miles."

"Here's what gets lost in the GAAP noise: Clarivate generated $628.5 million in operating cash flow in 2025 against a net loss of $201.1 million. That gap exists almost entirely because of $757.2 million in depreciation and amortization from years of acquisitions. The business bleeds cash in, not out."

"We believe selling this segment will allow further emphasis on the A&G and IP market and strengthen our balance sheet through reduced leverage. We are currently engaged in active discussions with interested parties."

Clarivate operates as a largely overlooked data intelligence company providing essential tools like Web of Science, Derwent, and Cortellis to researchers, patent attorneys, and pharmaceutical scientists. Despite trading at a low valuation of $2.64 per share with a $1.67 billion market cap, the company generated $628.5 million in operating cash flow in 2025 against a net loss of $201.1 million, with the gap explained by $757.2 million in depreciation and amortization from acquisitions. Free cash flow reached $365.3 million in 2025, with management guiding for $365 million to $435 million in 2026. The company is actively selling its Life Sciences and Healthcare segment with Morgan Stanley's assistance to reduce its $4.47 billion debt load and strengthen its balance sheet while emphasizing its Academic and Government and Intellectual Property market segments.

Read at 24/7 Wall St.